Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 15 - Drugs for genital or sexual disorders; Contraceptives
Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
10/2003
10/23/2003US20030199491 Quinoline derivatives having vegf inhibiting activity
10/23/2003US20030199484 Method for the treatment of urinary incontinence
10/23/2003US20030199456 Sodium channel blockers
10/23/2003US20030199103 Novel amino acid sequences for human epidermal growth factor-like polypeptides
10/23/2003US20030199043 Therapeutic proteins (including polypeptide, antibody, peptide or fragment or variants)fused to albumin or fragment or variant linked by a linker peptide; nonglycosylated
10/23/2003US20030198975 Proteins associated with cell growth, differentiation, and death
10/23/2003CA2482382A1 Pyrazole compounds as anti-inflammatory and analgesic agents
10/23/2003CA2481747A1 Recombinant anti-interleukin-9 antibodies
10/23/2003CA2481603A1 Method and composition for improving fertility health in female and male animals and humans
10/23/2003CA2481532A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003CA2481391A1 Preventives/remedies for hotflash
10/23/2003CA2481387A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003CA2481372A1 Method to inhibit cell growth using oligonucleotides
10/23/2003CA2481282A1 Protein a compositions and methods of use
10/23/2003CA2481240A1 Aminocarbonyl substituted pyridines, pyridazines, pyrimidines, pyrazines and triazines having antiangiogenic activity
10/23/2003CA2481207A1 Methods of treatment using ctla-4 antibodies
10/23/2003CA2480763A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
10/23/2003CA2480758A1 Tyrosine kinase inhibitors
10/23/2003CA2480754A1 Tyrosine kinase inhibitors
10/23/2003CA2480745A1 Methods for treating tweak-related conditions
10/23/2003CA2480415A1 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
10/23/2003CA2480410A1 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
10/23/2003CA2480213A1 Use of interleukin-19 to treat ovarian cancer
10/23/2003CA2477692A1 Cyanamides useful as reversible inhibitors of cysteine proteases
10/22/2003EP1354953A1 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/22/2003EP1354948A1 Novel cancer-associated genes
10/22/2003EP1354882A1 Dipeptidyl peptidase iv inhibitor
10/22/2003EP1353952A2 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
10/22/2003EP1353938A1 Androgenic 7-substituted 11-halogenated steroids
10/22/2003EP1353927A2 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/22/2003EP1353918A1 Morpholine derivatives as antagonists of orexin receptors
10/22/2003EP1353916A2 Pyrazole compounds useful as protein kinase inhibitors
10/22/2003EP1353914A2 Therapeutic chromone compounds
10/22/2003EP1353913A2 Therapeutic heterocyclic compounds
10/22/2003EP1353896A2 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
10/22/2003EP1353727A2 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
10/22/2003EP1353700A1 Compositions of estrogen-cyclodextrin complexes
10/22/2003EP1353699A1 Cyclodextrin-drospirenone inclusion complexes
10/22/2003EP1353675A2 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/22/2003EP1353672A2 Synthesis of 3-amino-thalidomide and its enantiomers
10/22/2003EP1353664A2 Heterocycle derivatives and methods of use for treating anthrax infection
10/22/2003EP1056754B1 Phosphate derivatives of diaryl 1,3,4-oxadiazolone
10/22/2003EP1047665B1 Matrix metalloprotease inhibitors
10/22/2003EP0699069B9 Endothelin receptor antagonists
10/22/2003CN1451010A Benzosulfones with calcium antagonist activity
10/22/2003CN1451004A 7-oxo pyridopyrimidines
10/22/2003CN1450907A Beta glycan as an inhibin receptor and uses thereof
10/22/2003CN1450894A Phenylethylamines and condensed rings variants as prodrugs of catecholamines and their use
10/22/2003CN1450892A Mesoprogestins (progesterone receptor modulators) for treatment and prevention of hormone dependent gynecological
10/22/2003CN1449834A Use of 2-hydroxypropyl beta-cyclodextrin in preparing sodium new houttuy fonate injection
10/22/2003CN1449784A Compound Zedoary Turmeric oil preparation and process for making same
10/22/2003CN1449778A Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying
10/22/2003CN1449776A Chinese medicine formula for treating acyesis
10/22/2003CN1449771A Repellent mixture for department of gynecology
10/22/2003CN1449767A Painless milkphobic and weaning preparation for external use
10/22/2003CN1449763A Soy daidzin composition and preparation process and use thereof
10/22/2003CN1449760A Composition of danazol semisolid skeleton preparation
10/22/2003CN1124852C Kiduey reinforcing and life essence producing pill
10/22/2003CN1124848C Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
10/21/2003US6635744 Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders
10/21/2003US6635739 Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
10/21/2003US6635680 Controlled release pellet formulation
10/21/2003US6635672 Agent for lowering prolactin
10/21/2003US6635669 Kinase inhibitor; benign prostatic hyperplasia
10/21/2003US6635650 Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders
10/21/2003US6635638 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
10/21/2003US6635256 Administering multiple domain glycoprotein hormones containing alpha subunit covalently linked to beta subunit to form single chain hormone and additional beta subunit noncovalently linked to tethered alpha subunit of single chain hormone
10/21/2003US6635242 Nursing bottle comprising container for breast milk, cap portion and nipple, and microbiocidal composition comprising sodium dodecyl sulfate, lithium dodecyl sulfate or lauric acid and salts in amount viricidal against non-enveloped virus
10/21/2003CA2240136C Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
10/21/2003CA2213737C 2-arylbenzazole compounds
10/21/2003CA2037884C Stabilized gonadotropin containing preparations
10/16/2003WO2003084963A1 Non-steroidal progesterone receptor modulators
10/16/2003WO2003084956A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
10/16/2003WO2003084954A1 Tropane derivatives as ccr5 modulators
10/16/2003WO2003084949A1 Pyridinoylpiperidines as 5-ht1f agonists
10/16/2003WO2003084943A2 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003WO2003084609A1 Preparation for treating climacteric post-menopausal complaints, containing a dehydroepiandrosterone and an estradiol
10/16/2003WO2003084582A1 Embolization
10/16/2003WO2003084552A1 Composition for the topical treatment of vulvovaginitis and mycoses
10/16/2003WO2003084549A1 Hormone replacement therapy
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084526A1 Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003066030A3 Pharmaceutical tablet
10/16/2003WO2003066029A3 Pharmaceutical dosage form for mucosal delivery
10/16/2003WO2003057729A3 Mammal prolactin variants
10/16/2003WO2003047504A3 Prevention and treatment of androgen-deprivation induced osteoporosis
10/16/2003WO2003039439A3 Deuterated pyrazolopyrimidinones and drugs containing said compounds
10/16/2003WO2003011314A3 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
10/16/2003WO2003010192A3 An inducer of apoptosis
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2003005036A3 Epf receptor assays, compounds and therapeutic compositions
10/16/2003WO2002100849A3 Novel nitriles useful as reversible inhibitors of cysteine proteases
10/16/2003WO2002085299A3 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/16/2003WO2002079220A3 Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
10/16/2003WO2002055086A3 Hormone replacement therapy method and its administration form
10/16/2003WO2002054064A3 Method for screening for progesterone receptor isoform-specific ligands
10/16/2003WO2002036151A3 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
10/16/2003US20030196217 Desaturase genes, enzymes encoded thereby, and uses thereof
10/16/2003US20030195261 Administering racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate for prophylaxis or therapy
1 ... 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 ... 557